Publication: Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer
Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer
Date
Date
Date
Citations
Rosalia, R. A., Arenas-Ramirez, N., Bouchaud, G., Raeber, M. E., & Boyman, O. (2014). Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Current Opinion in Chemical Biology, 23C, 39–46. https://doi.org/10.1016/j.cbpa.2014.09.006
Abstract
Abstract
Abstract
The use of interleukin-2 (IL-2) for the stimulation of an effector immune response against metastatic cancer dates back to the early 1980s. Administration of unmodified IL-2, either alone or together with antigen-specific approaches, has resulted in remarkably long-term survival of some patients suffering from metastatic melanoma. However, such treatment is usually hampered by the appearance of toxic adverse effects, which has motivated the engineering of modified IL-2 formulations showing reduced toxicity while being more potent at s
Metrics
Downloads
Views
Additional indexing
Creators (Authors)
- Rosalia, Rodney A
- Arenas-Ramirez, Natalia
- Bouchaud, Grégory
- Raeber, Miro E
- Boyman, Onur
Volume
Volume
Volume
Page range/Item number
Page range/Item number
Page range/Item number
Page end
Page end
Page end
Item Type
Item Type
Item Type
In collections
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Dewey Decimal Classifikation
Language
Language
Language
Publication date
Publication date
Publication date
Date available
Date available
Date available
ISSN or e-ISSN
ISSN or e-ISSN
ISSN or e-ISSN
OA Status
OA Status
OA Status
Publisher DOI
Metrics
Downloads
Views
Citations
Rosalia, R. A., Arenas-Ramirez, N., Bouchaud, G., Raeber, M. E., & Boyman, O. (2014). Use of enhanced interleukin-2 formulations for improved immunotherapy against cancer. Current Opinion in Chemical Biology, 23C, 39–46. https://doi.org/10.1016/j.cbpa.2014.09.006
